Business Description
Imunon Inc
NAICS : 325412
SIC : 2834
ISIN : US15117N5032
Description
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.67 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.6 | |||||
| 3-Year FCF Growth Rate | 33.6 | |||||
| 3-Year Book Growth Rate | -40.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.1 | |||||
| 9-Day RSI | 39.43 | |||||
| 14-Day RSI | 46.43 | |||||
| 6-1 Month Momentum % | -19.02 | |||||
| 12-1 Month Momentum % | -29.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.47 | |||||
| Quick Ratio | 2.47 | |||||
| Cash Ratio | 2.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51.3 | |||||
| Shareholder Yield % | 5.25 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -89.56 | |||||
| ROA % | -60.46 | |||||
| ROIC % | -389.65 | |||||
| ROC (Joel Greenblatt) % | -1089.55 | |||||
| ROCE % | -84.36 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.79 | |||||
| Price-to-Tangible-Book | 0.79 | |||||
| EV-to-EBIT | 0.17 | |||||
| EV-to-Forward-EBIT | -0.04 | |||||
| EV-to-EBITDA | 0.18 | |||||
| EV-to-FCF | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.09 | |||||
| Price-to-Net-Cash | 1.48 | |||||
| Earnings Yield (Greenblatt) % | 588.24 | |||||
| FCF Yield % | -184.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imunon Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.022 | ||
| Beta | 0.8 | ||
| Volatility % | 141.93 | ||
| 14-Day RSI | 46.43 | ||
| 14-Day ATR (€) | 0.110327 | ||
| 20-Day SMA (€) | 1.1975 | ||
| 12-1 Month Momentum % | -29.72 | ||
| 52-Week Range (€) | 0.438 - 1.84 | ||
| Shares Outstanding (Mil) | 9.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imunon Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imunon Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imunon Inc Frequently Asked Questions
What is Imunon Inc(FRA:CBO)'s stock price today?
The current price of FRA:CBO is €1.05. The 52 week high of FRA:CBO is €1.84 and 52 week low is €0.44.
When is next earnings date of Imunon Inc(FRA:CBO)?
The next earnings date of Imunon Inc(FRA:CBO) is 2024-05-10 Est..
Does Imunon Inc(FRA:CBO) pay dividends? If so, how much?
Imunon Inc(FRA:CBO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers